Getting started
First Month on an Oral GLP-1: Starting Semaglutide or Orforglipron Tablets
Last clinically reviewed: July 20, 2026 by Dr. Prajeet Reddy, MD (Medical Director)

Oral GLP-1 medications let you get the appetite-regulating effects of this drug class in a daily tablet instead of a weekly injection. There are two very different kinds, and your first month looks a little different on each:
- Oral semaglutide (the tablet form of the molecule in Wegovy and Ozempic) — a peptide that is destroyed by food, so it comes with strict empty-stomach rules.[2][3]
- Orforglipron (Foundayo) — a small-molecule GLP-1 that is not affected by food, so it has no eating or drinking restrictions.[6][7]
Both are FDA-approved, both start at a low dose, and both share the same family of mostly temporary stomach-related side effects.[1]
Week 1: Learning the Routine
If you're on oral semaglutide, the routine is the whole ballgame:
- Take your tablet first thing in the morning, on an empty stomach
- Swallow it whole with no more than 4 ounces (about half a glass) of plain water — no coffee, juice, or sparkling water
- Wait at least 30 minutes before eating, drinking anything else, or taking any other oral medications
- Do not split, crush, or chew the tablet
These rules exist because semaglutide is a peptide: food, other liquids, or too much water can drastically reduce how much of the medication your body absorbs.[2] Many people use the 30-minute window to shower, get dressed, or exercise.
If you're on orforglipron (Foundayo): take one tablet at roughly the same time each day — morning or evening, with or without food, any beverage you like. That's it.[6]
What you may feel in week 1: often very little. Starting doses are intentionally low — typically 3 mg for daily oral semaglutide (or the lowest tablet strength of oral Wegovy) and 0.8 mg for orforglipron, depending on your prescription — and are there mainly to let your body adjust.[2][7]
Weeks 2–3: Appetite Changes Arrive
What you may notice:
- Feeling full sooner at meals and staying full longer
- Less interest in snacking; food "noise" quieting down
- Mild nausea, especially after large or fatty meals
- Constipation or occasional loose stools
Tips that carry most people through this phase:[9]
- Eat smaller meals, slowly, and stop at "satisfied" — overeating is the most common nausea trigger
- Limit greasy, fried, and very sweet foods
- Sip water steadily through the day (after your 30-minute window, if on semaglutide)
- For constipation: fiber, fluids, and a daily walk
Week 4: Settling In — and Looking Ahead
By the end of the first month, most people have the routine down and early side effects are fading. Weight change in month 1 is usually modest — the low starting dose is doing adjustment work, not heavy lifting. Meaningful weight loss builds over the following months as your dose steps up on your provider's schedule:
- Oral semaglutide 25 mg produced an average 13.6% weight loss over 64 weeks in the OASIS 4 trial.[5][4]
- Orforglipron produced an average of roughly 11% weight loss at the highest dose over 72 weeks in ATTAIN-1 (about 10% in adults with type 2 diabetes in ATTAIN-2).[7][8]
Your provider will typically hold each dose for at least 4 weeks before increasing, and can slow the schedule any time side effects need to settle.
Missed Doses
For both medications: skip the missed dose and take your next one at the usual time the next day. Never take two doses in one day to catch up.[2] For oral semaglutide specifically, if you remember after you've already eaten, wait until the next morning — the tablet will not absorb properly on a full stomach.
Side Effects: What's Normal, What's Not
Normal and usually temporary: mild-to-moderate nausea, constipation, diarrhea, burping, reduced appetite, mild fatigue. These cluster in the first weeks and around dose increases, then improve.[4][9] In clinical trials, only about 6–10% of participants stopped the medication because of side effects — about 9 in 10 people were able to continue.[5][7]
Call your provider promptly if you have:
- Vomiting or inability to keep fluids down for more than 24 hours
- Signs of dehydration (dark urine, dizziness, rapid heartbeat)
- Severe, persistent abdominal pain — possible pancreatitis or gallbladder disease[2]
- Rash, facial swelling, or trouble breathing
Habits That Make Month 1 Easier
- Anchor the pill to an existing habit — semaglutide next to your toothbrush for the morning routine; orforglipron with any daily anchor you already have
- Protein first at every meal (eggs, Greek yogurt, chicken, fish, beans) to protect muscle as weight loss begins[10]
- Move most days — even walking counts toward the 150 weekly minutes that pair best with these medications[11]
- Judge progress monthly, not daily. The first month is about tolerance and routine; the results phase comes with the higher doses.
Talk with your care team before changing how you take your medication, and bring any questions about your dose schedule to your first follow-up visit.
Frequently asked questions
How do I take oral semaglutide correctly?
First thing in the morning, on an empty stomach, with no more than 4 ounces (half a glass) of plain water. Then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Swallow the tablet whole — do not split, crush, or chew it. Taking it with food, too much water, or other liquids can drastically reduce absorption.
Does orforglipron (Foundayo) have the same food and water rules?
No — that's its main convenience advantage. Orforglipron is a small-molecule GLP-1 that can be taken at any time of day, with or without food, and with no water restrictions. Just take it at roughly the same time each day to build the habit.
What if I miss a dose of my oral GLP-1?
Skip the missed dose and take your next dose at the usual time the next day. Do not double up. For oral semaglutide, if you've already eaten when you remember, wait until the next morning — the tablet won't absorb properly on a full stomach.
How many people stop oral GLP-1s because of side effects?
Relatively few. In clinical trials, roughly 6–10% of participants discontinued because of side effects — meaning about 9 in 10 people were able to continue. Most side effects are mild-to-moderate nausea or digestive changes that cluster around dose increases and improve with time.
Sources
- FDA Orange Book: Approved Drug Products
- OZEMPIC / Oral Semaglutide Prescribing Information — DailyMed (FDA)
- WEGOVY Prescribing Information — DailyMed (FDA)
- Oral Semaglutide for Weight Management — Cochrane Review 2025
- Oral Semaglutide 25 mg in Adults with Overweight or Obesity (OASIS 4) — NEJM 2025
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity — Phase 2, NEJM 2023
- Orforglipron in Adults with Obesity (ATTAIN-1) — NEJM 2025
- Orforglipron in Adults with Obesity and Type 2 Diabetes (ATTAIN-2) — Lancet 2025
- Managing Adverse Effects of Incretin-Based Medications for Obesity — Kushner et al., JAMA 2025
- Nutritional Priorities to Support GLP-1 Therapy for Obesity — Joint Advisory, Am J Clin Nutr 2025
- Lifestyle Modification and Incretin-Based Therapy for Obesity — Kushner et al., JAMA 2026
This article is for education and does not replace your prescriber’s instructions or the FDA Medication Guide that comes with your medication. Clinical content reviewed by Dr. Prajeet Reddy, MD, Medical Director (Cyane Medical Group California PC).
$29/mo membership — the lowest in GLP-1 telehealth. No contracts.